। บ.บ । /บ UU I I I I I I I r - Trim H - W 中欣氟材 -7697.17 6.49% 班 빵 服 第□财经 当天机构净卖出前三的股票分别是中欣氟材、博威合金、中国长城，净流出金额分别是7697万元、6341万元、 6079万元。 | | 龙虎榜榜08.13 | F | | --- | --- | --- | | 证券简称 | 目涨跌幅 | 机构净买入 (万元) | | 创新医疗 | 10.00% | 10079.77 | | 江特电机 | 1.99% | 8933.17 | | 沪电股份 | 10.00% | 7292.01 | | 罗博特科 | 20.00% | 6905.96 | | 北纬科技 | 10.04% | 4191.31 | | 威尔高 | 6.99% | 4175.57 | | 中船特气 | 20.01% | 3763.92 | | 东方精工 | 10.03% | 2724.97 | | 恒信东方 | -18.83% | 2691.15 | | 浙江华小 | 2.73% | 1643.22 | | --- | --- | --- | | 麦澜德 | -3 ...

截至6月30日，创新医疗股东户数8.2万，人均流通股5074股。 8月13日，创新医疗盘中10.0%涨停，截至13:12，报22.65元/股，成交30.18亿元，换手率33.41%，总市 值99.95亿元。 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇郑家湖村，公司的主营业务是提供医 疗服务，旗下包括建华医院、康华医院、福恬医院和明珠医院四家医疗机构，致力于满足患者需求和提 高医疗质量。公司通过精细化管理，科室建设，人才引培等方式以提升核心竞争力，同时关注行业政 策，进行供应链整合，以优化医疗资源和提高治疗效果。 2025年1月-6月，创新医疗实现营业收入4.02亿元，同比减少1.60%；归属净利润-1136.13万元，同比增 长29.12%。 来源：金融界 ...

8月13日，创新医疗盘中上涨5.34%，截至09:34，报21.69元/股，成交6.49亿元，换手率7.36%，总市值 95.71亿元。 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇郑家湖村，公司的主营业务是提供医 疗服务，旗下包括建华医院、康华医院、福恬医院和明珠医院四家医疗机构，致力于满足患者需求和提 高医疗质量。公司通过精细化管理，科室建设，人才引培等方式以提升核心竞争力，同时关注行业政 策，进行供应链整合，以优化医疗资源和提高治疗效果。 2025年1月-6月，创新医疗实现营业收入4.02亿元，同比减少1.60%；归属净利润-1136.13万元，同比增 长29.12%。 截至6月30日，创新医疗股东户数8.2万，人均流通股5074股。 ...

Group 1 - The market focus stocks include Jishi Media, which opened high at 9.79% after achieving five consecutive trading days of gains [1] - Robotics concept stock Beiwai Technology opened flat, while Feiyada opened high at 2.57% after three consecutive trading days of gains [1] - Local Xinjiang stock Hongtong Gas opened high at 4.95% after five consecutive trading days of gains, and Beixin Road and Bridge opened high at 0.54% [1] Group 2 - The consumer electronics sector saw Furi Electronics open high at 1.15% after five consecutive trading days of gains [1] - In the chip industry chain, Haili Co. opened high at 2.31% after four consecutive trading days of gains, while Wantong Development opened low at 0.87% [1] - In the computing power industry chain, Huasheng Tiancai opened high at 2.94% after three consecutive trading days of gains, and Tongzhou Electronics reached a limit-up in bidding [1] Group 3 - Brain-computer interface concept stock Innovation Medical opened high at 2.53% after three consecutive trading days of gains [1]

8月9日公司发布的半年报数据显示，上半年公司共实现营业总收入4.02亿元，同比下降1.60%，实现净 利润-0.11亿元，同比增长29.12%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.11 | 6.36 | 35.46 | 20137.65 | | 2025.08.08 | 0.74 | 41.42 | -16735.13 | | 2025.08.07 | 10.01 | 30.10 | 22618.18 | | 2025.08.06 | -2.16 | 25.49 | -15482.08 | | 2025.08.05 | 10.03 | 25.23 | 47179.97 | | 2025.08.04 | -1.14 | 13.61 | -3170.00 | | 2025.08.01 | -2.74 | 19.68 | -11350.39 | | 2025.07.31 | 7.72 | 18.39 | 12252.95 | | 2025.07.30 | -0.07 | 8 ...

Group 1 - The A-share market has seen a strong performance in brain-computer interface concept stocks, with notable increases in share prices for several companies [1] - Major gainers include Mailland, which rose nearly 18%, and Xiangyu Medical, which increased over 10% [1] - Other companies such as Qisheng Technology and Innovation Medical reached their daily limit up of 10%, while Chengyitong and Sanbo Brain Science rose over 8% [1] Group 2 - Detailed stock performance includes: - Mailland (688273) with a 17.99% increase and a market cap of 5.28 billion, year-to-date increase of 129.09% [2] - Xiangyu Medical (688626) with a 10.33% increase and a market cap of 10.2 billion, year-to-date increase of 119.06% [2] - Qisheng Technology (603610) with a 10.01% increase and a market cap of 5.083 billion, year-to-date increase of 15.14% [2] - Innovation Medical (002173) with a 9.99% increase and a market cap of 9.086 billion, year-to-date increase of 158.67% [2] - Chengyitong (300430) with an 8.37% increase and a market cap of 6.329 billion, year-to-date increase of 51.81% [2] - Sanbo Brain Science (301293) with an 8.19% increase and a market cap of 12.8 billion, year-to-date increase of 43.94% [2] - Aipeng Medical (300753) with a 6.54% increase and a market cap of 4.601 billion, year-to-date increase of 107.58% [2] - Weisi Medical (688580) with a 5.91% increase and a market cap of 5.376 billion, year-to-date increase of 104.65% [2] - Lepu Medical (300003) with a 5.61% increase and a market cap of 34.4 billion, year-to-date increase of 62.75% [2]

【脑机接口概念股震荡走高 创新医疗6天3板】智通财经8月12日电，创新医疗6天3板，麒盛科技此前涨 停，倍益康涨超10%，诚益通、三博脑科、爱朋医疗、南京熊猫（维权）、佳禾智能等跟涨。消息面 上，工信部等七部门近日发布《关于推动脑机接口产业创新发展的实施意见》。其中提出，到2027年， 脑机接口关键技术取得突破，初步建立先进的技术体系、产业体系和标准体系。 转自：智通财经 ...

Group 1 - The brain-computer interface sector is experiencing a significant rise, with several companies showing strong performance [1] - Innovative Medical has reached its daily limit increase, indicating strong investor interest and confidence [1] - Qi Sheng Technology previously hit its limit up, reflecting positive market sentiment towards the company [1] Group 2 - Companies such as Xiangyu Medical, Mcland, and Beiyikang have all seen their stock prices increase by over 10%, showcasing a broader trend of growth in the sector [1] - Other companies including Aipeng Medical, Chengyitong, Sanbo Brain Science, Weisi Medical, and Lihua Science and Technology are also experiencing upward movement in their stock prices [1]

Core Viewpoint - Innovation Medical reported a decline in total revenue and a significant increase in net loss, indicating challenges in the current operational environment [2][3]. Operational Overview - As of the reporting period, total revenue was 402 million yuan, a year-on-year decrease of 1.6%. The net profit attributable to shareholders was -11.36 million yuan, an increase of 29.12% year-on-year. The net profit after deducting non-recurring items was -12.88 million yuan, up 22.42% year-on-year. In Q2 alone, total revenue was 208 million yuan, a year-on-year increase of 0.73%, with a net profit of 2.58 million yuan, up 119.74% year-on-year [2]. Profitability Analysis - The company's profitability showed signs of recovery, with a gross margin of 12.06%, an increase of 2.27% year-on-year. The net margin was -2.79%, up 28.4% year-on-year. However, the company remains in a loss position, with earnings per share at -0.03 yuan, an increase of 25.0% year-on-year. The net asset per share was 4.0 yuan, down 4.82% year-on-year [3]. Cash Flow and Expense Control - The net cash flow from operating activities significantly improved, with operating cash flow per share at 0.19 yuan, a staggering increase of 2578.88% year-on-year. However, cash and cash equivalents decreased to 249 million yuan, down 55.17% from 556 million yuan in the same period last year. Accounts receivable were 74.89 million yuan, a decrease of 39.67% year-on-year. The ratio of three expenses (selling, administrative, and financial expenses) to revenue was 13.88%, an increase of 10.15% year-on-year [4]. Main Business Composition - The company's main business revenue is almost entirely derived from medical services, amounting to 400 million yuan, which accounts for 99.73% of total revenue, with a gross margin of 11.82%. Other business revenue was 1.09 million yuan, representing 0.27% of total revenue, with a high gross margin of 88.56%. Regionally, Heilongjiang had the highest revenue at 236 million yuan, accounting for 58.70% of total revenue, with a gross margin of 12.78%. Zhejiang's revenue was 147 million yuan, making up 36.73% of total revenue, with a gross margin of 10.99% [5]. Development Review and Outlook - During the reporting period, the company maintained a competitive advantage in the complex environment of the medical service industry. Four hospitals—Jianhua Hospital, Kanghua Hospital, Fu Tian Hospital, and Mingzhu Hospital—hold significant market positions in their respective regions. Jianhua Hospital optimized and integrated functional departments to reduce operating costs and enhance management efficiency, while Kanghua Hospital achieved slight revenue growth. Fu Tian Hospital experienced a decline in revenue and efficiency due to adjustments in medical insurance payment policies [6]. Financial Health Assessment - Despite a recovery in profitability, the company's cash flow situation and expense control require attention. The average operating cash flow to current liabilities ratio over the past three years was -6.09%, and the average net cash flow from operating activities over the past three years was negative, indicating a need for improvement in cash flow management and expense control [7].

Group 1 - The brain-computer interface (BCI) concept stocks have been active, with multiple stocks rising significantly, and several exceeding 100% increase in price year-to-date [1][3][4] - A recent policy document issued by seven government departments aims to accelerate the BCI industry's development, proposing 17 specific measures to enhance hardware and software capabilities, application of technological achievements, and support for innovation [2][4] - The document outlines a roadmap for BCI development, with milestones set for 2025 and 2027, including the establishment of a comprehensive support system and the cultivation of leading enterprises [5][6] Group 2 - The policy encourages various application scenarios, including industrial manufacturing, healthcare, and consumer applications, aiming to break down departmental barriers and enhance collaboration across the industry [7][8] - The BCI industry is transitioning from research to commercialization, with significant advancements in non-invasive technologies and ongoing efforts to develop core components domestically [8][9] - The medical sector is identified as the fastest-growing area for BCI commercialization, with a projected global market size of $40 billion by 2030, driven by the treatment of central nervous system diseases [9][10] Group 3 - Recent developments include the establishment of pricing for BCI medical services, with specific costs outlined for invasive and non-invasive procedures, providing a foundation for clinical application [12][13] - Several listed companies are actively engaging in the BCI sector, with ongoing research and product development in invasive and semi-invasive BCI applications [13][15] - Companies are also preparing to establish funds and partnerships to support innovation and investment in the BCI field, indicating a strong interest in the sector's growth [14][15]